Core Laboratories Inc.
CLB
$10.44
-$0.16-1.51%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 130.16M | 123.59M | 129.24M | 134.40M | 130.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 130.16M | 123.59M | 129.24M | 134.40M | 130.58M |
| Cost of Revenue | 103.70M | 99.47M | 106.20M | 106.81M | 102.93M |
| Gross Profit | 26.46M | 24.12M | 23.04M | 27.59M | 27.65M |
| SG&A Expenses | 10.16M | 13.37M | 8.79M | 8.33M | 9.97M |
| Depreciation & Amortization | 3.67M | 3.72M | 3.66M | 3.68M | 3.77M |
| Other Operating Expenses | -144.00K | -785.00K | -221.00K | -1.01M | -887.00K |
| Total Operating Expenses | 117.39M | 115.77M | 118.44M | 117.80M | 115.79M |
| Operating Income | 12.77M | 7.82M | 10.80M | 16.60M | 14.79M |
| Income Before Tax | 12.58M | 1.82M | 11.55M | 16.70M | 12.80M |
| Income Tax Expenses | 1.91M | 1.75M | 4.08M | 4.69M | 3.61M |
| Earnings from Continuing Operations | 10.67M | 69.00K | 7.47M | 12.00M | 9.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -33.00K | -223.00K | -66.00K | -259.00K | -158.00K |
| Net Income | 10.64M | -154.00K | 7.40M | 11.75M | 9.03M |
| EBIT | 12.77M | 7.82M | 10.80M | 16.60M | 14.79M |
| EBITDA | 16.44M | 11.53M | 14.47M | 20.27M | 18.56M |
| EPS Basic | 0.23 | 0.00 | 0.16 | 0.25 | 0.19 |
| Normalized Basic EPS | 0.13 | 0.06 | 0.10 | 0.18 | 0.15 |
| EPS Diluted | 0.22 | 0.00 | 0.16 | 0.25 | 0.19 |
| Normalized Diluted EPS | 0.13 | 0.06 | 0.10 | 0.18 | 0.14 |
| Average Basic Shares Outstanding | 46.63M | 46.77M | 47.77M | 46.92M | 46.91M |
| Average Diluted Shares Outstanding | 47.36M | 46.77M | 47.77M | 47.82M | 47.74M |
| Dividend Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Payout Ratio | 4.41% | -304.55% | 6.34% | 3.99% | 5.20% |